Arlington Asset Investment Corp(AAIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AAIC Arlington Asset Investment Corp

Closed 06-20 16:00:00 EDT

4.84

+0.00

0.00%

High4.84	Low4.84	Vol0.00
Open4.84	D1 Closing4.84	Amplitude0.00%
Mkt Cap137.08M	Tradable Cap130.81M	Total Shares28.32M
T/O0.00	T/O Rate0.00%	Tradable Shares27.03M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AAIC","market":"US","secType":"STK","nameCN":"Arlington Asset Investment Corp","latestPrice":4.84,"timestamp":1750449600000,"preClose":4.84,"halted":0,"volume":0,"delay":0,"floatShares":27027890,"shares":28322726,"eps":-0.078991,"marketStatus":"Closed","change":0,"latestTime":"06-20 16:00:00 EDT","open":4.84,"high":4.84,"low":4.84,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.078991,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"listingDate":882853200000,"exchange":"NYSE","adjPreClose":4.84,"dividendRate":0.046488,"volumeRatio":0},"requestUrl":"/m/hq/s/AAIC/tweets","defaultTab":"tweets","newsList":[{"id":"2583454536","title":"“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2583454536","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583454536?lang=en_us&edition=fundamental","pubTime":"2025-11-14 07:30","pubTimestamp":1763076600,"startTime":"0","endTime":"0","summary":"TOKYO and CAMBRIDGE, Mass., Nov.  13, 2025  (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/13/3187962/0/en/LEQEMBI-lecanemab-IV-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimer-s-Disease-Approved-in-the-United-Kingdom.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCI","BK4132","UBCP","BK4110","BK4211","AAIC","AD"],"gpt_icon":0},{"id":"2569278099","title":"Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa","url":"https://stock-news.laohu8.com/highlight/detail?id=2569278099","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569278099?lang=en_us&edition=fundamental","pubTime":"2025-09-22 21:15","pubTimestamp":1758546900,"startTime":"0","endTime":"0","summary":"Exploring potential partnerships and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s diseaseAlzheimer’s disease development program with positive data in successful ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/22/3153988/0/en/Longeveron-to-Attend-Alliance-for-Regenerative-Medicine-s-Cell-Gene-Meeting-on-the-Mesa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4575","MSC","AAIC","AD","LGVN","BK4150","BK4139","BK4110","BK4132"],"gpt_icon":0},{"id":"2563072015","title":"FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2563072015","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563072015?lang=en_us&edition=fundamental","pubTime":"2025-08-30 05:00","pubTimestamp":1756501200,"startTime":"0","endTime":"0","summary":"LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatme","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/29/3141816/0/en/FDA-Approves-LEQEMBI-IQLIK-lecanemab-irmb-Subcutaneous-Injection-for-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARIA","AAIC","BK4132","BK4110","MCI","BK4080","CSF","CDR","AD","HF","CAA"],"gpt_icon":0},{"id":"2558644404","title":"Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2558644404","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558644404?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:30","pubTimestamp":1754998200,"startTime":"0","endTime":"0","summary":"Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug.  12, 2025  (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/12/3131586/29248/en/Anavex-Life-Sciences-Reports-Fiscal-2025-Third-Quarter-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","DB","BK4156","BK4118","BK4585","BK4135","BK4566","AVXL","BK4588","BK4139","AAIC","BK4110","BK4552"],"gpt_icon":0},{"id":"2557991455","title":"INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2557991455","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557991455?lang=en_us&edition=fundamental","pubTime":"2025-08-08 04:05","pubTimestamp":1754597100,"startTime":"0","endTime":"0","summary":"Company to Host Conference Call Today, August 7th, at 4:30pm ETBOCA RATON, Fla., Aug.  07, 2025  (GLOBE NEWSWIRE) -- INmune Bio Inc.(NASDAQ: INMB) (the “Company”), a clinical-stage immunology company ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/07/3129702/0/en/INmune-Bio-Inc-Announces-Second-Quarter-2025-Results-Provides-Business-Update-and-Announces-Management-Changes.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4215","INMB","BK4139","AAIC","MAA","BK4110","BK4585","BK4588"],"gpt_icon":0},{"id":"2557566548","title":"Annovis Completes Full Patent Transfer to Crystal Buntanetap","url":"https://stock-news.laohu8.com/highlight/detail?id=2557566548","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557566548?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:00","pubTimestamp":1754568000,"startTime":"0","endTime":"0","summary":"Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new crystalline forms of buntanetap. Both forms are covered by a total of 13 pa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/07/3129189/0/en/Annovis-Completes-Full-Patent-Transfer-to-Crystal-Buntanetap.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","BK4181","BK4588","BK4136","PD","IP","LU1169589451.USD","BK4023","AAIC","LU2463526074.USD","BK4110","LU1481599808.USD","PK","BK4585","BK4218","LU1487256676.USD","LU1169590202.USD","BK4139","ANVS","LU1481600234.SGD"],"gpt_icon":0},{"id":"2555028159","title":"Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2555028159","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555028159?lang=en_us&edition=fundamental","pubTime":"2025-07-30 23:00","pubTimestamp":1753887600,"startTime":"0","endTime":"0","summary":"TOKYO and CAMBRIDGE, Mass., July  30, 2025  (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/30/3124251/0/en/Two-Year-Real-World-Study-of-LEQEMBI-in-the-United-States-Presented-at-Alzheimer-s-Association-International-Conference-AAIC-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","UBCP","BK4211","AAIC","MCI"],"gpt_icon":0},{"id":"2555004458","title":"NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2555004458","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555004458?lang=en_us&edition=fundamental","pubTime":"2025-07-30 20:25","pubTimestamp":1753878300,"startTime":"0","endTime":"0","summary":"-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, in both the full analysis set (p=0.0019) and in ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/30/3124045/0/en/NewAmsterdam-Pharma-Presents-Positive-Data-from-BROADWAY-Trial-Demonstrating-Statistically-Significant-Reductions-in-Key-Alzheimer-s-Disease-Biomarkers-at-AAIC-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BYFC","AAIC"],"gpt_icon":0},{"id":"2555056271","title":"ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2555056271","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555056271?lang=en_us&edition=fundamental","pubTime":"2025-07-29 20:00","pubTimestamp":1753790400,"startTime":"0","endTime":"0","summary":"Presentation to highlight the Company’s proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company’s Phase 1b clinical trial design and o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/29/3123184/0/en/ProMIS-Neurosciences-to-Showcase-Protein-Misfolding-Drug-Discovery-Platform-PRECISE-AD-Trial-Design-at-the-2025-Alzheimer-s-Association-International-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1815336091.USD","BK4023","LU2211815571.USD","BK4526","MSA","PK","BK4600","USA","BK4143","LU1923622291.USD","LU0728928796.USD","LU0053671581.USD","BK4595","AAIC","BK4110","PD","LU0757428866.USD","ARIA","LU2125909759.SGD","LU1169590202.USD","LU1169589451.USD","BK4170","BK4218","LU2125909916.SGD","BK4181"],"gpt_icon":1},{"id":"2555056899","title":"Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2555056899","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555056899?lang=en_us&edition=fundamental","pubTime":"2025-07-29 19:30","pubTimestamp":1753788600,"startTime":"0","endTime":"0","summary":"- Zervimesine’s impact on debilitating DLB behavioral symptoms highlighted in podium presentation -- Plasma p-tau217 levels can identify Alzheimer’s patients most likely to benefit from zervimesine tr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/29/3123138/0/en/Cognition-Therapeutics-Presents-Data-at-AAIC-Highlighting-Broad-Neurological-Impact-of-Zervimesine-CT1812-in-Dementia-with-Lewy-Bodies-and-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345774391.USD","BK4007","BK4080","CGTX","LENZ","BK4097","CDR","AAIC","LU0205194284.USD","LU0205193047.USD","DLB","CAF","BK4110","BK4539","LU0345774631.USD","LU0348723411.USD","LU0240877869.USD","CSF","BK4139","LU0240878834.USD"],"gpt_icon":0},{"id":"2554775528","title":"CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2554775528","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554775528?lang=en_us&edition=fundamental","pubTime":"2025-07-28 19:00","pubTimestamp":1753700400,"startTime":"0","endTime":"0","summary":"Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/28/3122322/0/en/CervoMed-Announces-32-Week-Data-from-RewinD-LB-Trial-Extension-Phase-Showing-Neflamapimod-s-Sustained-Effect-on-Slowing-Clinical-Progression-in-Patients-with-Dementia-with-Lewy-Bod.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","LB","BK4233","BK4213","AAIC","CRVO","BK4139"],"gpt_icon":0},{"id":"2554733637","title":"CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2554733637","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554733637?lang=en_us&edition=fundamental","pubTime":"2025-07-25 04:05","pubTimestamp":1753387500,"startTime":"0","endTime":"0","summary":"Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference (AAIC) 2025 Conference call and web","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/24/3121425/0/en/CervoMed-to-Present-New-Data-from-Phase-2b-RewinD-LB-Study-at-AAIC-2025-and-Host-Conference-Call-on-July-28-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","CRVO","BK4139","LU0205194284.USD","LU0345774631.USD","LU0240877869.USD","BK4218","LU0240878834.USD","BK4181","BK4233","BK4585","HST","DLB","LB","BK4588","BK4110","LU0345774391.USD","BK4213","LU0348723411.USD","LU0205193047.USD","AAIC"],"gpt_icon":0},{"id":"2553032788","title":"INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2553032788","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553032788?lang=en_us&edition=fundamental","pubTime":"2025-07-24 19:00","pubTimestamp":1753354800,"startTime":"0","endTime":"0","summary":"Boca Raton, July  24, 2025  (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro, a novel selective soluble TNF i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/24/3120917/0/en/INmune-Bio-to-Present-Phase-2-MINDFuL-Trial-Findings-of-XPro-at-the-Alzheimer-s-Association-International-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1216","LU0607220059.USD","AAIC","BK4110","LU0149534421.HKD","01821","INMB"],"gpt_icon":0},{"id":"2553255337","title":"NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2553255337","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553255337?lang=en_us&edition=fundamental","pubTime":"2025-07-22 20:00","pubTimestamp":1753185600,"startTime":"0","endTime":"0","summary":"– NewAmsterdam to host conference call at 10:00 a.m. ET on Wednesday, July 30th –NAARDEN, the Netherlands and MIAMI, July  22, 2025  (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/22/3119383/0/en/NewAmsterdam-Pharma-to-Present-Alzheimer-s-Biomarker-Data-from-BROADWAY-Trial-at-AAIC-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","WRAP","AAIC","BK4195","BK4157","BK4211","BYFC"],"gpt_icon":0},{"id":"2551363140","title":"Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC","url":"https://stock-news.laohu8.com/highlight/detail?id=2551363140","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551363140?lang=en_us&edition=fundamental","pubTime":"2025-07-16 19:30","pubTimestamp":1752665400,"startTime":"0","endTime":"0","summary":"- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/16/3116291/0/en/Cognition-Therapeutics-Positive-Clinical-Data-from-Zervimesine-CT1812-Phase-2-Study-in-Dementia-with-Lewy-Bodies-DLB-will-be-Presented-in-a-Podium-Presentation-at-AAIC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345774631.USD","LU0240878834.USD","LU0345774391.USD","CDR","AAIC","LU0348723411.USD","BK4110","DLB","BK4080","LU0240877869.USD","CAF","BK4539","LENZ","BK4139","BK4097","LU0205194284.USD","BK4007","CGTX","LU0205193047.USD"],"gpt_icon":0},{"id":"2550985953","title":"Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2550985953","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550985953?lang=en_us&edition=fundamental","pubTime":"2025-07-11 20:00","pubTimestamp":1752235200,"startTime":"0","endTime":"0","summary":"Data from the Phase 1 clinical trial of novel KCNK13 inhibitor showed good CNS exposure and was generally well-toleratedProprietary NETSseq platform explores the key potential role of astrocytes in Al","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/11/3113944/0/en/Cerevance-Announces-Presentations-at-the-Alzheimer-s-Association-International-Conference-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","AAIC","CNS","BK4135"],"gpt_icon":0},{"id":"2549499715","title":"CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2549499715","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549499715?lang=en_us&edition=fundamental","pubTime":"2025-07-08 19:00","pubTimestamp":1751972400,"startTime":"0","endTime":"0","summary":"BOSTON, July  08, 2025  (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will delive","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/08/3111598/0/en/CervoMed-Announces-Late-Breaking-Presentations-at-Alzheimer-s-Association-International-Congress-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0240877869.USD","CRVO","BK4110","LU0345774391.USD","BK4139","LU0348723411.USD","AAIC","LU0205194284.USD","DLB","LU0240878834.USD","BK4097","LU0205193047.USD","LU0345774631.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arlingtonasset.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arlington Asset Investment Corp. (NYSE: AAIC) currently invests primarily in mortgage related and residential real estate and has elected to be taxed as a REIT. The Company is headquartered in the Washington, D.C. metropolitan area. For more information, please visit www.arlingtonasset.com.","yearOnYearQuotes":[{"month":1,"riseRate":0.576923,"avgChangeRate":0.036381},{"month":2,"riseRate":0.461538,"avgChangeRate":0.012132},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.040691},{"month":4,"riseRate":0.692308,"avgChangeRate":0.090423},{"month":5,"riseRate":0.461538,"avgChangeRate":0.01975},{"month":6,"riseRate":0.461538,"avgChangeRate":0.028757},{"month":7,"riseRate":0.269231,"avgChangeRate":-0.036613},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.04005},{"month":9,"riseRate":0.346154,"avgChangeRate":-0.02828},{"month":10,"riseRate":0.307692,"avgChangeRate":0.850529},{"month":11,"riseRate":0.653846,"avgChangeRate":-0.004218},{"month":12,"riseRate":0.5,"avgChangeRate":0.022688}],"exchange":"NYSE","name":"Arlington Asset Investment Corp","nameEN":"Arlington Asset Investment Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arlington Asset Investment Corp(AAIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arlington Asset Investment Corp(AAIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arlington Asset Investment Corp,AAIC,Arlington Asset Investment Corp股票,Arlington Asset Investment Corp股票老虎,Arlington Asset Investment Corp股票老虎国际,Arlington Asset Investment Corp行情,Arlington Asset Investment Corp股票行情,Arlington Asset Investment Corp股价,Arlington Asset Investment Corp股市,Arlington Asset Investment Corp股票价格,Arlington Asset Investment Corp股票交易,Arlington Asset Investment Corp股票购买,Arlington Asset Investment Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arlington Asset Investment Corp(AAIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arlington Asset Investment Corp(AAIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction